#高警訊藥品

乳癌、肝癌、急性非淋巴性白血病、多發性硬化症
Breast cancer; Hepatoma; Acute nonlymphoblastic leukemia; Multiple sclerosis

Antineoplastic Agent, Anthracenedione; Topoisomerase II Inhibitor
Mitoxantrone is believed to exert its cytotoxic effect by interfering with the function of topoisomerase II, thereby preventing religation of DNA strand breaks.

Distribution:
1. Vdss: >1,000 L/m2; extensively into kidney, liver, heart, lung, and bone marrow, but does not cross the blood brain barrier
2. Protein binding: 78%
Metabolism:
Hepatic; Half-life elimination: 23 to 215 hours
Excretion:
Feces (25%); urine (11%; 65% as unchanged drug)

1. Hypersensitivity to mitoxantrone or any component of the formulation; presence of severe myelosuppression due to prior chemo- and/or radiotherapy
2. Severe hepatic impairment
3. Intrathecal administration

D

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued before starting treatment.

Leukopenia, nausea, vomiting, alopecia, anorexia, diarrhea, dyspnea, fatigue, weakness, fever, GI bleeding, stomatitis, mucositis

Multiple sclerosis:
IV: 12 mg/m2 every 3 months (maximum lifetime cumulative dose: 140 mg/m2; discontinue with LVEF <50% or clinically significant reduction in LVEF)

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

1. There are no dosage adjustments provided in the manufacturer's labeling; however, clearance is reduced in hepatic dysfunction (consider dose adjustments).
2. Patients with multiple sclerosis with hepatic impairment should not receive mitoxantrone.

Dextrose 5% in water with mitoxantrone 20ug/mL to 500ug/mL physically compatible and stable for 1 week at 25℃ or 4℃ in a polyvinylchloride container. At th same conditon NS keep stability for 48 hours at 25℃.